Company: STAA
Filing Date: 2025-12-11
Form Type: DFAN14A
Source: 0001213900-25-120777
Chunk: 20

Company: STAAR SURGICAL CO
Filing Date: 2025-12-11
Form: DFAN14A
Chunk 20
---
 to vote against the proposed merger, even at the revised price. There may come a time when a board of STAAR should sell the Company, but now is not the right time, and the current Board is not the right board for the job , having lost credibility with shareholders in our view… We will continue to vote our shares AGAINST the amended merger agreement and urge all shareholders to do the same.” 1 Christopher Min Fang Wang Chief Investment Officer Yunqi Capital Limited (owner of 5% of STAAR’s outstanding shares) 2 1. Source: Yunqi Capital Limited Press Release, December 10, 2025. 2. Source: Yunqi Capital Limited Amended Schedule 13D, filed with the SEC on November 3, 2025.

Broadwood Partners, L.P. Better Alternatives Continue to Exist for Stockholders 31 Reject the transaction Reconstitute the Board and management team as necessary Potential for significant value creation as a standalone company, with strategic optionality once the Company is in a stronge r p osition ▪ Broadwood is in the process of calling a special meeting of shareholders to remove the STAAR directors who we believe bear primary responsibility for orchestrating this flawed sale process and transaction ▪ Broadwood is not seeking control of the Board, but stands ready to recruit and nominate new directors and executives who are capable of realizing the value associated with STAAR’s bright future ▪ Ramp up production at the Company’s new Switzerland facility and continue working with partners in China to optimize inventory levels ▪ Continue the work of the Capital Stewardship Committee to refine the Company’s capital allocation strategy ▪ Further reduce SG&A ▪ Launch EVO+ lens and localize manufacturing in China ▪ The Company’s continued recovery, along with a more cooperative macroeconomic environment, could support a significantly higher valuation in a sale ▪ Alternatively, the Company is well positioned to drive long - term value for stockholders as an independent company Continue to execute strategic initiatives and return the Company to growth Reevaluate strategic alternatives from a position of strength

Broadwood Partners, L.P. STAAR Has a Bright Future as a Standalone Company 32 There are many reasons to be optimistic about STAAR’s prospects as an independent company if the Proposed Merger is rejected ▪ STAAR’s EVO ICLs offer many advantages over competing treatments, including a lower likelihood of dry eye, a shorter recovery ti me, removability and UV protection ▪ Recent data demonstrating the superiority of ICLs indicate that